FB23-2 (FB23-2; FB-23-2; FB 232) is a novel, potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO with potential antineoplastic activity. It inhibits FTO with an IC50 of 2.6 μM and exhibited high inhibitory effects in vivo against AML models. FB23-2 directly binds to FTO and selectively inhibit FTO's m6A demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro. Moreover, FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice. Collectively, our data suggest that FTO is a druggable target and that targeting FTO by small-molecule inhibitors holds potential to treat AML.

纯度：≥98%

CAS：2243736-45-8